Overt Hepatic Encephalopathy Market Research Report Information by Type (Covert and Overt), Disease Severity (Type A, Type B and Type C), Diagnosis (Blood Test, Liver Function Test, Detection of Serum Ammonia Levels, Encephalogram and others), Treatment (Lactulose, Antibiotics, Probiotics, Branched-Chain Amino Acids, Liver Transplantation and others), End User (Hospitals & Clinics, Research Institutes, Surgical Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2032.

Overt Hepatic Encephalopathy Market Overview

The Overt Hepatic Encephalopathy Market is projected to reach USD 0.42 Billion by 2032 at 8.2% CAGR during the forecast period 2023-2032.

Hepatic encephalopathy is a complication of end-stage liver disease. It develops in patients who have cirrhosis. Symptoms of overt hepatic encephalopathy are a metabolic disturbance, gastrointestinal bleeding, and liver infection. 

Overt Hepatic Encephalopathy Market will notice an increased growth rate due to the higher rate of disease cases, leading to various treatment options. The shortfall of approved therapies provides a place for emerging therapies; due to this, the market will notice huge opportunities. The demand for medications with safety, effectiveness, and optimum cure is emerging in the market.

The lack of knowledge in clinical courses and clinical relevance may hinder the market’s growth. The availability of pharmacological therapies has limited the usage of temporary relief. The demand from the healthcare sector for more effective treatment procedures is driving the market. The developments of key players to meet the public’s demand will accelerate the market to reach its value in the forecast period.

Segmentation

The Global Overt Hepatic Encephalopathy Market has been segmented based on type, disease security, diagnosis, treatment, end user, and region.

The global overt hepatic encephalopathy market, based on type, has been divided into covert and overt. The overt segment is expected to hold a major share in the market due to the rising prevalence of liver disease globally.

The global overt hepatic encephalopathy market, based on disease security, has been segmented into Type A, Type B, and Type C.

The global overt hepatic encephalopathy market, based on diagnosis, has been segmented into blood tests, liver function test, detection of serum ammonia levels, encephalogram, and others.

The global overt hepatic encephalopathy market, based on treatment, is divided into lactulose, antibiotics, probiotics, branched-chain amino acids, liver transplantation, and others.

Based on end user, the global overt hepatic encephalopathy market is segmented into hospitals & clinics, research institutes, surgical centers, and others.

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The overt hepatic encephalopathy market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European overt hepatic encephalopathy market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The overt hepatic encephalopathy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The overt hepatic encephalopathy market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

The Key Players operating in the Global Overt Hepatic Encephalopathy Market are Alfa Wassermann S.P.A, Cosmo Pharmaceuticals S.P.A, Horizon Pharma Plc., KannaLife Sciences, Inc., Ocer Therapeutics, Rebiotix Inc., Spherium Biomed S.L, Umecrine Cognition AB, ASKA Pharmaceutical, Mallinckrodt, Valeant, and Norgine B.V.

Regional Market Summary

Global Overt Hepatic Encephalopathy Market Share, by Region, 2018 (%)  

Source: World Health Organization (WHO)

The Americas are expected to dominate the market during the forecast period due to the growing number of geriatric individuals and the presence of major established players in the region. Moreover, the developed healthcare infrastructure in the US is expected to drive the growth of the market in the region.

The overt hepatic encephalopathy market in Europe showed a considerable amount of growth, which can be attributed to the presence of a well-established healthcare system, increasing diagnosis of liver diseases, and the presence of major companies in the region.

The overt hepatic encephalopathy market in Asia-Pacific is projected to register a steady growth rate during the forecast period owing to the growing hepatic encephalopathy patient pool and increasing government initiatives for healthcare reforms.

The overt hepatic encephalopathy market in the Middle East & Africa is projected to account for the least share of the market due to the low per capita disposable income in the region.

Global Overt Hepatic Encephalopathy Market, by Type

• Covert


• Overt

Global Overt Hepatic Encephalopathy Market, by Disease Severity

• Type A 


• Type B


• Type C

Global Overt Hepatic Encephalopathy Market, by Diagnosis

• Blood Tests


• Liver Function Test


• Detection of Serum Ammonia Levels


• Encephalogram


• Others

Global Overt Hepatic Encephalopathy Market, by Treatment

• Lactulose


• Antibiotics


• Probiotics


• Branched-Chain Amino Acids


• Liver Transplantation


• Others

Global Overt Hepatic Encephalopathy Market, by End User  

• Hospitals & Clinics


• Research Institutes


• Surgical Centers


• Others

Global Overt Hepatic Encephalopathy Market, by Region

• 
  Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • Latin America
  
  
  
  

• 
  Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • UK
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  

• 
  Asia-Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  

• 
  Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Recent Development

In April 2022

Salix Pharmaceuticals, a gastroenterology business of Bausch Health Companies Inc, which is the largest specialty pharmaceutical company in the world, has announced its prevention and treatment of gastrointestinal diseases. The company announced four posters data for XIFAXAN (rifaximin) and RELISTO (methylnaltrexone bromide) at the Society of Hospital Medicine (SHM) Converge 2022 annual meet in Nashville, Tenn., from April 7 to 10, 2022. Rifaximin Treatment for Hepatic Encephalopathy can reduce the emergency days in Emergency Department Services Versus Lactulose Alone.

In June 2021

Axcella is a global clinical-stage biotechnology company that offers a new approach to treating complex diseases and improving health using endogenous metabolic modulator compositions. It has announced the activation of initial clinical sites and patient screening for the Phase 2 clinical trial of AXA1665. The company target oral product to reduce the risk of recurrent overt hepatic encephalopathy.Intended Audience

• Research and development (R&D) companies


• Government research institutes


• Academic institutes and universities


• Venture capitalists